Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Heron Therapeutics (DE:AXD2)
FRANKFURT:AXD2
RESEARCH TOOLSreports
Heron Therapeutics (AXD2) Stock Price & Analysis
2 Followers
AXD2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€0.51 - €2.80
Previous Close€2.72
Volume0.00
Average Volume (3M)826.00
Market Cap
€390.24M
Enterprise Value€460.84M
Total Cash (Recent Filing)$80.41M
Total Debt (Recent Filing)$155.37M
Price to Earnings (P/E)N/A
Beta1.24
Next Earnings
May 09, 2024EPS Estimate
-€0.06Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding150,328,585
10 Day Avg. Volume50
30 Day Avg. Volume826
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-12.97
Price to Sales (P/S)3.23
Price to Cash Flow (P/CF)44.90
P/FCF Ratio18.10
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.63
Enterprise Value/Gross Profit7.44
Enterprise Value/Ebitda-4.38
Forecast
1Y Price Target
€6.59Price Target Upside142.14% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Heron Therapeutics News
PremiumCompany Announcements
Heron Therapeutics Announces New Principal Accounting Officer
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
1.59% Other Institutional Investors
98.41% Public Companies and
Individual Investors
AXD2 FAQ
What was Heron Therapeutics’s price range in the past 12 months?
Heron Therapeutics lowest stock price was €0.51 and its highest was €2.80 in the past 12 months.
What is Heron Therapeutics’s market cap?
Currently, no data Available
When is Heron Therapeutics’s upcoming earnings report date?
Heron Therapeutics’s upcoming earnings report date is May 09, 2024 which is in 20 days.
How were Heron Therapeutics’s earnings last quarter?
Heron Therapeutics released its earnings results on Mar 12, 2024. The company reported -€0.066 earnings per share for the quarter, beating the consensus estimate of -€0.145 by €0.079.
Is Heron Therapeutics overvalued?
According to Wall Street analysts Heron Therapeutics’s price is currently Undervalued.
Does Heron Therapeutics pay dividends?
Heron Therapeutics does not currently pay dividends.
What is Heron Therapeutics’s EPS estimate?
Heron Therapeutics’s EPS estimate is -€0.06.
How many shares outstanding does Heron Therapeutics have?
Currently, no data Available
What happened to Heron Therapeutics’s price movement after its last earnings report?
Heron Therapeutics reported an EPS of -€0.066 in its last earnings report, beating expectations of -€0.145. Following the earnings report the stock price went up 10.435%.
Which hedge fund is a major shareholder of Heron Therapeutics?
Among the largest hedge funds holding Heron Therapeutics’s share is Fortitude Family Office, LLC. It holds Heron Therapeutics’s shares valued at 477.
---
Heron Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€6.59 (142.14% Upside)
€6.59 (142.14% Upside)
Blogger Sentiment
Bullish
DE:AXD2 Sentiment 80%
Sector Average 70%
Sector Average 70%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-3.48%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-11.33%
Trailing 12-Months
Company Description
Heron Therapeutics
Heron Therapeutics, Inc. is a biotechnology company, which develops pharmaceutical products for patients suffering from cancer. The company develops products by using its proprietary Biochronomer polymer based drug delivery technology. Its products include SUSTOL, Pipeline, Cinvanti and HTX-011. The company has additional clinical and preclinical-stage programs in the area of pain management, all of which utilize its bio erodible, injectable and implantable delivery systems. Heron Therapeutics was founded in February 1983 and is headquartered in Redwood City, CA.
---
AXD2 Company Deck
---
AXD2 Earnings Call
Q4 2024
0:00 / 0:00
---
AXD2 Stock 12 Months Forecast
Average Price Target
€6.59
▲(142.14% Upside)
Technical Analysis
ANI Pharmaceuticals
―
Corbus Pharmaceuticals
―
Eagle Pharmaceuticals
―
Innoviva
―
Heron Therapeutics
―
Best Analysts Covering AXD2
1 Year
1 Year Success Rate
13/46 ratings generated profit
1 Year Average Return
-1.22%
reiterated a buy rating 5 months ago
Copying Boris Peaker's trades and holding each position for 1 Year would result in 28.26% of your transactions generating a profit, with an average return of -1.22% per trade.
---